How a protein affects nicotine receptors in the brain
Visinin-like protein-1 modulation of nicotinic receptors
This study is looking at how a specific protein affects the way nicotine works in the brain, with the goal of finding better ways to help people quit smoking. If you're someone trying to stop using nicotine, your experiences might help researchers discover new treatments that could make quitting easier.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alaska Fairbanks NIH-funded |
| Lab location | 1 site (Fairbanks, United States) |
| Project ID | NIH-10897276 on NIH RePORTER |
What this research studies
This research investigates the role of visinin-like protein-1 in modulating nicotinic receptors, which are crucial for understanding nicotine addiction. The study aims to explore how changes in these receptors can influence nicotine use disorder and potentially improve cessation strategies. By examining the sensitivity of different receptor isoforms, the research seeks to identify new therapeutic targets for helping individuals quit smoking. Patients may be involved in assessments that evaluate their nicotine use and response to potential treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are struggling with nicotine addiction or are interested in quitting smoking.
Not a fit: Patients who do not smoke or are not interested in quitting nicotine will likely not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for nicotine addiction, helping patients quit smoking and reduce health risks associated with tobacco use.
How similar studies have performed: While the specific approach of modulating visinin-like protein-1 is novel, similar studies targeting nicotinic receptors have shown promise in improving cessation outcomes.
Where this research is happening
Fairbanks, United States
- University of Alaska Fairbanks — Fairbanks, United States (Active)
Researchers
- Principal investigator: Weltzin, Maegan M — University of Alaska Fairbanks
- Study coordinator: Weltzin, Maegan M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.